作者hahawow (哇哈哈)
看板medstudent
标题Re: [新闻] 糖尿病药梵帝雅 有条件续用
时间Fri Jul 16 19:56:47 2010
: 推 c2yuan:这是class effect吧﹗？只要同类药都一样才对... 07/16 12:53
http://www.nytimes.com/2010/07/13/health/policy/13avandia.html?_r=1
Avandia’s success was crucial to SmithKline, whose labs were otherwise all
but barren of new products. But the study’s results, completed that same
year, were disastrous. Not only was Avandia no better than Actos, but the
study also provided clear signs that it was riskier to the heart.
But instead of publishing the results, the company spent the next 11 years
trying to cover them up, according to documents recently obtained by The
New York Times. The company did not post the results on its Web site or
submit them to federal drug regulators, as is required in most cases by law.
--
※ 发信站: 批踢踢实业坊(ptt.cc)
◆ From: 123.192.172.15
1F：→ rambler:纽时八卦起来口吻其实不输小报嘛...jama最新的这篇有提到 07/17 00:21
3F：推 c2yuan:感谢, 不过楼上这篇只能说Rosiglitazone比Pioglitazone 07/17 13:20
4F：→ c2yuan:有较高的stroke....风险, 并不代表Pioglitazone是正常... 07/17 13:21
5F：推 c2yuan:Both thiazolidinediones have been shown to increase the 07/17 13:25
6F：→ c2yuan:risk of heart failure compared with treatment 07/17 13:26
7F：→ c2yuan:with placebo or other antidiabetes medications 07/17 13:26
8F：→ c2yuan:(以上为文章内的一段话...) 07/17 13:27
9F：→ c2yuan:可以看该篇文章33,34的REFERENCES 07/17 13:28
10F：→ hahawow:heart failure之外其他是否class effect恐怕证据还不够 07/17 17:14